This pivotal study demonstrated that the addition of atezolizumab to bevacizumab plus chemotherapy significantly improved PFS and OS among patients with metastatic non-squamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status [201]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.